A review on newly approved PARP inhibitors: Talazoparib and Olaparib
This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.
Huvudupphovsman: | Karim, Azrin |
---|---|
Övriga upphovsmän: | Islam, Farzana |
Materialtyp: | Project report |
Språk: | English |
Publicerad: |
Brac University
2024
|
Ämnen: | |
Länkar: | http://hdl.handle.net/10361/24372 |
Liknande verk
-
A review on potential of PARP inhibitors in the treatment of prostate cancer
av: Islam, Saidul
Publicerad: (2022) -
Association of XRCC1 and XPD polymorphism with risk of prostate cancer in Bangladesh population
av: Ahmed, Nafisa
Publicerad: (2023) -
SHP2 inhibitors: Recent advancements and potential breakthroughs in cancer therapy
av: Meem, Manila
Publicerad: (2023) -
Mutation in DNA polymerase γ: mitochondrial disorders
av: Hossain, Sadman Sanjid
Publicerad: (2023) -
RIPK pathway, as a potential target, for cancer treatment - a review
av: Jahan, Nusrat
Publicerad: (2024)